Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115880 | 0.92 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL3121346 | 0.92 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL3105861 | 0.90 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL3118662 | 0.90 | MAPK14 (0.51) | MAPK14 | |
| SCHEMBL3338394 | 0.89 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL3114262 | 0.89 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL1140673 | 0.88 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL3107262 | 0.86 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL1399805 | 0.86 | MAPK14 (0.37) | MAPK14 | |
| SCHEMBL3109174 | 0.86 | MAPK14 (0.48) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB | 2010-10-07 | — | — | US | claimed |
| EP-1915350-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007020411-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | claimed |
| US-20100256120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256120-A1 | AMIDE DERIVATIVES | IL1B, IL1A, IL6 | MAPK14 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.